GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nicox SA (XPAR:ALCOX) » Definitions » Accounts Payable

Nicox (XPAR:ALCOX) Accounts Payable : €1.65 Mil (As of Dec. 2024)


View and export this data going back to 1999. Start your Free Trial

What is Nicox Accounts Payable?

Nicox's Accounts Payable for the quarter that ended in Dec. 2024 was €1.65 Mil.

Nicox's quarterly Accounts Payable declined from Dec. 2023 (€2.50 Mil) to Jun. 2024 (€1.58 Mil) but then increased from Jun. 2024 (€1.58 Mil) to Dec. 2024 (€1.65 Mil).

Nicox's annual Accounts Payable declined from Dec. 2022 (€2.54 Mil) to Dec. 2023 (€2.50 Mil) and declined from Dec. 2023 (€2.50 Mil) to Dec. 2024 (€1.65 Mil).


Nicox Accounts Payable Historical Data

The historical data trend for Nicox's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nicox Accounts Payable Chart

Nicox Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.42 3.65 2.54 2.50 1.65

Nicox Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.54 3.53 2.50 1.58 1.65

Nicox Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.


Nicox Accounts Payable Related Terms

Thank you for viewing the detailed overview of Nicox's Accounts Payable provided by GuruFocus.com. Please click on the following links to see related term pages.


Nicox Business Description

Traded in Other Exchanges
Address
Rue Evariste Galois, Emerald Square, Batiment C, Sundesk Sophia Antipolis, Biot, FRA, 06410
Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Its lead program in clinical development is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company also has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos. Its first product, VYZULTA in glaucoma, licensed exclusively worldwide to Bausch + Lomb, is available commercially in the U.S. and over 15 other territories. Nicox generates revenue from ZERVIATE in allergic conjunctivitis, licensed in multiple geographies.

Nicox Headlines

No Headlines